

Introduction to



Your partner in Healthcare



Mission



” We aim to become long-term trusted partners for venture investors and family offices providing valuable decision criteria for investment opportunities in the Healthcare sector.

Simon Nebel, PhD
Founder and Managing Partner, CEO

” Together with our collaboration partners we provide a wide range of tailor-made services and advice to clients from the Healthcare industry such as fundraising, business strategy, licensing and M&A.

Thomas Meier, PhD
Managing Partner



Mission



” As experienced entrepreneurs we know what it takes to successfully develop a life science business – we are not just advisors, we truly act as partners.

Ulf Grawunder, PhD
Managing Partner



” As entrepreneurial team we uniquely combine scientific expertise and financial proficiency for our clients and partners active in the healthcare industry.

Daniel Pajer, CFO
Managing Partner

The Team



Simon Nebel, PhD, MBA

Founder and Managing Partner, CEO



Over the past 20 years, Simon was involved in 4 Private Equity vehicles in healthcare and renewable energy as Managing Partner at Aravis with combined assets in excess of USD 300M. These funds invested in over 25 companies of which 19 healthcare companies; 13 healthcare companies either became public companies (SWX, ATX & NASDAQ) or were acquired. In 2016 Simon founded Viopas Venture Consulting where he is Managing Partner.

Simon has extensive experience as Board of Directors from public & private companies. He currently holds four Board positions.

Simon holds a master and a PhD in structural biology from the Biozentrum, University of Basel as well as an MBA from the London Business School.

Current Board Mandates



Chairman of the Board

Public company (ATX-Prime: MARI), Wien
Technology platform to treat respiratory and ophthalmic conditions. 6 Products on the market.



Member of the Board

Private Company (Oss, Netherlands)
Best-in-class, clinical-stage antibody-drug conjugate (ADC) technology platform



Member of the Board

Private Company (La Jolla, USA)
Clinical stage biotech developing innovative immuno-inflammatory regulators



Member of the Board

Private Company (Baar, Switzerland)
Digital Health company providing search engine for structured exchange of medical information

Thomas Meier, PhD

Managing Partner



Thomas is a dynamic life-science entrepreneur who established Santhera Pharmaceuticals (SIX Exchange: SANN) as successful Biotech/Specialty Pharma company in the Basel area (Switzerland). In the past 20 years he held executive manager positions (CSO and CEO) at Santhera and successfully executed merger/acquisitions, product licensing and turn-around situations.

He stepped down as Santhera's CEO in late 2019 and became Managing Partner at Viopas Venture Consulting in 2020. Currently Thomas holds three Board positions.


Thomas has a PhD in Biology and is lecturer in neurosciences at the Biozentrum, University of Basel. He is an internationally recognized scientist with track record in clinical research of orphan diseases.

Current Board Mandates



**Founder, Member of the Board,
Chairman of the Scientific Committee**

Public company (Basel)
Dedicated to treatments in rare diseases



**Member of the Board,
Member of the Development Committee**

Private Company (Basel, Israel)
Treatment of neuropathic pain

Ulf Grawunder, PhD

Managing Partner




Ulf Grawunder is a successful serial Biotech entrepreneur, who since 2004 has founded three Biotech companies, of which two have exited to other companies by trade-sale. In 2004 he co-founded the therapeutic antibody discovery company 4-Antibody in Basel, where he initially served as start-up CEO and later as CSO, until the company was sold to US-based Agenus Inc. In 2012 Ulf founded NBE-Therapeutics, active in the area of antibody-drug conjugates for cancer therapy. Ulf built NBE-Therapeutics from inception to the trade-sale of the company to Boehringer Ingelheim for US\$ 1.4 billion in 2021. Since recently, Ulf is co-founder of T-CURX from Würzburg, Germany, developing CAR-T cell therapies for cancer patients.

A biochemist by training, Ulf received his PhD from the Basel Institute for Immunology. During his academic career he worked at Washington University School of Medicine (USA), the University of Southern California (USA) and the Basel Institute for Immunology. Ulf also holds a Diploma of Technology Entrepreneurship from the University St. Gallen.

Ulf is advisor and teaching faculty member of several institutions, including the immune elite master studies program (Erlangen, Germany), the Swiss Venturekick start-up program, the European Center for Pharmaceutical Medicine (Basel). Ulf also serves as Vice-president and Board member of the Swiss Biotech Association.

Current Board Mandates



Vice President and Board Member

Public company (Basel)
Dedicated to treatments in rare diseases



Co-founder

Private Company (Würzburg, Germany)
Treatment of cancer

Daniel Pajer

Managing Partner, CFO



Daniel Pajer is a senior audit professional and consultant who built his expertise in finance, governance, risk management and compliance over the past 25 years. For the last 10 years he was an Equity Partner with PwC Switzerland.

During his career he served a wide range of clients in the financial services industry and he specialized in the institutional asset management business and its global operations. Daniel's particular interest is dedicated to the financing of venture capital and the management of private markets funds. His expertise covers organizational, structuring, legal, tax and regulatory requirements of the business.

Daniel enjoys working on demanding client projects and he gained extensive leadership experience as a department head, career coach and during his two-year secondment in the PwC Network. He holds a federal diploma as a certified public accountant and is a 2022 Executive Master in Business Administration candidate.

At Viopas Venture Consulting Daniel will act as the CFO responsible also for compliance topics.

Current Board Mandates




Member of the Foundation Board

Not for profit foundation (Basel area)
Institution for adults with cerebral palsy or multiple disabilities

Our Services



We identify investment opportunities and support businesses across the value chain



Early project scouting by access to academic networks, entrepreneurs, and incubators

Support start-ups in pre-seed and seed stage as friendly challengers

Interacting with founders/management/VCs to **identify attractive investment cases**

Support promising companies as business or finance advisors and Board members

Advise on selected late-stage investment opportunities, especially with **attractive risk/return profile, early exit potential**

Support mature companies in business development (e.g., product license, divestment or M&A)

For the Healthcare Investor

How we support your investment decision

We support
private investors
and family
offices



Evaluate and present
investment opportunities from
the Healthcare sector



Review of existing
portfolios



Prioritize investment
opportunities



Prepare risk
assessments



Due diligence (technology,
market positioning, competitive
intelligence, finance)




Represent investors vis a vis the
Company (e.g., as member of
the Board of Directors)

For the Healthcare Investor

VVC - trusted partner for your healthcare investment portfolio




... your support in building a Healthcare investment portfolio



For the Healthcare Business

How we support your business – together with our Strategic Partners

We support businesses in Digital Health/ MedTech and Pharma/Biotech



Regional Focus



We identify investment opportunities and support Healthcare businesses in Europe - with special emphasis on Switzerland, Austria, Germany




Therapeutics



Digital Health



Diagnostics



Strategic Partnerships



Board Advisors



In 2020
Simon and Thomas
of Viopas Venture
Consulting became
operational
partners of
Board Advisors



<https://www.boardadvisors.de>



10
ADVISORS



5
OFFICES



150+
YEARS
EXPERIENCE



2005
FOUNDED



€ 1 BN
DEAL VALUE



2020
BECAME
PARTNERS



Board Advisors' Vision and Mission



” We guide businesses throughout their lifecycle, engaging at key transition points, applying our expertise in the critical areas that drive success.

Christoph Löslein,
Founding Partner Board Advisors

ESTABLISHED COMPANIES



As **entrepreneurs and operators** in technology companies, large and small, we know what it's like to walk in your shoes (or similar ones).

We help you build your strategic plans and execution paths, including go-to-market plans, **identification of emerging markets, mergers and acquisitions, financing and executive development.**

ENTREPRENEURS AND VENTURES



Building a new company is exciting. **We are entrepreneurs ourselves** and have launched companies, financed and scaled companies and sold companies.

We can **finetune your business model**, we can help you with your **financial plans**, we can support building and implementing your **go-to-market strategy**, and we can help **prepare and manage your fundraising.**


INVESTORS



Our team has worked **hand-in-hand with the most active financial sponsors** in the IT and Digital Health industry.

We can offer **our expertise throughout your investment cycle**, starting with your investment thesis, through market assessment, due diligence and deal execution, to integration support and exit.

We can work with you and your portfolio companies to **operationalize best practices** and **maximize value** by leveraging strategy, growth and cost drivers.



Viopas Venture Consulting
collaborates with abcDNA GmbH



<https://www.abcdna.xyz>



Luca Bolliger, PhD

Founder abcDNA GmbH



Luca joined the pharmaceutical industry as a Global Discovery Portfolio Manager in the Pharma Strategy Unit at Hoffmann-La Roche Ltd. He then pursued his career in the financial industry as a Fundamental Analyst at BT&T asset management, and as a freelance consultant. Subsequently, he was Director Business Development at Actelion before he joined Novimmune in the same function. In his last position as VP Corporate Licensing at Recordati Group Luca was member of the Executive Management responsible for licensing activities of Recordati with special emphasis on orphan diseases. He was also responsible for Recordati's alliances. Currently, Luca serves on the three Boards, including the Swiss Biotech Association.

Luca studied biochemistry at the ETH in Zürich and completed his undergraduate studies with a Master in Immunology followed by a PhD in biochemistry from at the Biozentrum, University of Basel in biochemistry. He also was a member of the Basel Institute for Immunology.

Current Board Mandates



Member of the Board

Clinical-stage private company (Lyon)
Dedicated to treatments in CNS



Member of the Board

Private Company (Root)
Dedicated to the discovery of molecules with new structural diversity



Member of the Board

Industry association (Zürich)
Swiss Biotech Industry Association



Contact



Contact

Viopas Venture Consulting GmbH



www.viopasventure.ch



Schwizerstrasse 20
8610 Uster/Zürich
Switzerland



Simon Nebel, PhD, MBA
Founder, Managing Partner, CEO
simon@viopasventure.ch

+41 79 326 65 36

[LinkedIn](#)



Ulf Grawunder, PhD
Managing Partner
ulf@viopasventure.ch

+41 78 609 52 88

[LinkedIn](#)



Thomas Meier, PhD
Managing Partner
thomas@viopasventure.ch

+41 78 756 34 05

[LinkedIn](#)



Daniel Pajer
Managing Partner, CFO
daniel@viopasventure.ch

+41 79 722 67 98

[LinkedIn](#)

Thank you